In patients with Kaposi's sarcoma (KS), human herpesvirus 8 (HHV-8
Human herpesvirus 8 (HHV-8) was recently detected in
Kaposi's sarcoma (KS) (11, 18, 30) and B-cell lymphomas (5, 39, 45) , as well as in other malignancies and in healthy individuals. HHV-8 is a type 2 gammaherpesvirus (genus Rhadinovirus) with sequence similarity to Epstein-Barr virus (EBV), herpesvirus saimiri (HVS), equine herpesvirus 2, murine herpesvirus 68, and two recently identified herpesviruses causing retroperitoneal fibromatosis in macaques (34, 40, 41, 48) . Although seroprevalence data indicated that HHV-8 is more widespread and not restricted to KS, HHV-8 is suspected of possessing transforming activity similar to EBV and HVS, which cause tumors in their natural hosts and in experimental animals (2, 15, 16, 19, 24, 27, 44) . In most cell lines established from KS tissue, HHV-8 is lost during continuous propagation. Several cell lines derived from primary effusion lymphoma (PEL) and KS, however, are stably infected by latent HHV-8 and can be induced to undergo lytic viral replication and virus production (6, 38, 42) . Serial propagation of HHV-8 on primary cells or cultured cell lines has not been possible thus far. In vitro, HHV-8 could be transferred to several cell lines and primary cells including 293 (13, 37) and B lymphocytes (25) ; however, this did not result in stable virus infection. In vivo, HHV-8 was detected in biopsy specimens of KS lesions (11, 18, 30) but also in prostate tissue (28) , semen (28) , saliva (47) , peripheral blood B lymphocytes (1, 10) , and lymphoid tissue (4) of KS patients. Human B lymphocytes can also be infected by EBV, the nearest relative of HHV-8 that is pathogenic to humans. EBV is able to transform B cells in vitro to permanent lymphoblastoid cell lines (LCLs) (20) . EBV-induced B-cell transformation leads to a sequential expression of at least 11 latent EBV genes (EBNAs, LMPs, and EBERs), entry into the cell cycle and continuous cell proliferation, RNA synthesis, and expression of activation (e.g., transferrin receptor, major histocompatibility complex class II, CD21, CD23, CD39, CD40 and CD44) and adhesion (e.g., ICAM1, LFA1, and LFA3) molecules, resulting in a phenotype similar to stimulated B cells. Thus far, there has been no experimental evidence that infectious HHV-8 particles can stably infect and transform either primary cells or cell lines in vitro. In this study, we present evidence that HHV-8 persistently infects peripheral blood B lymphocytes and that LCLs continuously infected with HHV-8 can be established.
MATERIALS AND METHODS
Blood donors. Peripheral blood mononuclear cells (PBMC) were isolated from EDTA-treated blood of four EBV-negative and EBV-positive healthy individuals by Ficoll-Hypaque discontinuous gradient centrifugation (Lymphoflot; Biotest AG, Dreieich, Germany) as specified by the manufacturer. Blood donors were not from HHV-8 risk groups. EBV serologic testing was performed with the following commercial kits detecting virus capsid antigen (VCA) immunoglobulin G (IgG) (Fresenius, Bad Homburg, Germany) and IgM (Viramed, Martinsried, Germany) and Epstein-Barr virus nuclear antigen (EBNA) IgG antibodies (Biotest, Dreieich, Germany). EBV-positive individuals were positive for VCA IgG and EBNA IgG antibodies but negative for VCA IgM antibodies. EBV-negative individuals were negative for VCA IgG, VCA IgM, and EBNA IgG.
Cell culture and EBV and/or HHV-8 infection. BCBL-1 (38), BC-1 (35), B95-8 (CRL1612), Raji (CCL 86), and LCLs were cultured in RPMI (Life Technologies, Paisley, Scotland) supplemented with 20% heat-inactivated fetal calf serum (FCS; Life Technologies), 100 IU of penicillin (Life Technologies) per ml, 100 mg of streptomycin (Life Technologies) per ml, 2 mM L-glutamine (Life Technologies), and 0.05 mM 2-mercaptoethanol (Sigma, St. Louis, Mo.). For cells at low density, the 2-mercaptoethanol was replaced by 20 mM bathocuproine disulfonic acid (Sigma), 50 m ␣-thioglycerol (Sigma), and 1 mM sodium pyruvate (Life Technologies). To induce the expression of lytic viral proteins, cells were treated with 20 ng of phorbol 12-myristate 13-acetate (TPA; Sigma) per ml and 3 mM sodium n-butyrate (Sigma) for 24 h.
Supernatants of either BCBL-1, BC-1, B95-8, or Raji cells grown at very high densities (5 ϫ 10 5 per ml) were used to infect PBMC. Supernatants were filtered through 0.4-m filters and serially diluted with cell culture medium in 96-well plates, and PBMC were added to 10 4 cells per well. For serial virus passage, supernatants of ABEH-1, ABE-1, GMEH-1, and GME-1 cells were generated similarly and added to 10 4 PBMC from an EBV ϩ donor. Isolation of cellular DNA and detection of viral DNA by PCR. Total cellular DNA was prepared from 10 6 cells by the method of Miller et al. (26) . The primer used to amplify HHV-8 DNA flanked the K12 open reading frame (K12for, 5Ј cggaattcatggatagaggcttaacg 3Ј; K12rev, 5Ј cgctcgagtcagtgcgcgcccgttgc 3Ј). The length of the expected amplified product is 196 bp. The primers used to amplify EBV DNA from the BALF5 open reading frame were Epolfor (5Ј aggttggcggg gctcagggc 3Ј) and Epolrev (5Ј agcacaggctagccggcctg 3Ј), and the amplified product was 343 bp in size. Each reaction mixture contained 500 ng of cellular DNA, 100 ng of each primer, and 5 U of Taq polymerase (Perkin-Elmer Cetus, Branchburg, N.J.). The mixture was cycled in a DNA thermal cycler 2400 (PerkinElmer) for 30 cycles of amplification (96°C for 1 min; 60°C for 1 min; 72°C for 1 min). One-tenth of the PCR products were analyzed on 2% agarose-40 mM Tris acetate-1 mM EDTA and visualized after ethidium bromide staining. As negative and positive PCR controls, water and plasmid DNAs of EBV polymerase and K12 cloned into pBluescript KS II ϩ were used, respectively. Preparation of RNA and RT-PCR. RNA was extracted from 10 6 cells with Tri Reagent (Molecular Research Center, Cincinnati, Ohio) as specified by the manufacturer. A 5-g portion of total RNA in 10 l of water and 1 g of oligo(dT) 18 primer were heated to 70°C for 10 min and then cooled to 4°C on ice. The oligonucleotide primers used in this study were K12for, K12rev, VP23for (5Ј cgcgggtctagaatcgcactcgacaagagtata 3Ј), VP23rev (5Ј cgcggggaattctttagcgtggggaatacc aacagga 3Ј), Actfor (5Ј cgcgaatccccccagtgtgacatgg 3Ј), and Actrev (5Ј cgcggatccc agccaggtccagacg 3Ј). As negative controls for these experiments, reverse transcription-PCR (RT-PCR) was performed with 1 g of total RNA. As negative and positive PCR controls, water and plasmid DNAs of full-length cDNA of VP23, actin, and K12 cloned into pBluescript KS IIϩ were used, respectively.
Flow cytometry. To analyze the surface phenotype of LCLs, BC-1 and BCBL-1 cells (5 ϫ 10 5 ) were washed in phosphate-balanced saline (PBS) and FACS buffer (PBS containing 2.5% FCS and 0.02% sodium azide) and stained directly with anti-CD3-phycoerythrin (PE), anti-CD14-PE, anti-CD16-PE, anti-CD19-PE, anti-CD56-PE (Pharmingen, Hamburg, Germany), anti-IgG-fluorescein isothiocynate (FITC), and anti-IgM-FITC (Sigma). Isotype controls were included in each assay. For indirect staining, cells were incubated first with mouse anti-CD19, anti-CD20, anti-CD23, or anti-CD30 (Dako Diagnostika, Hamburg, Germany) and then with goat anti-mouse IgG-FITC (Dianova, Hamburg, Germany). As the negative control, only goat anti-mouse IgG-FITC was used in each assay. The cells were washed three times and analyzed on a FACScan with Cellquest software (Becton Dickinson, San Jose, Calif.).
Immunofluorescence and confocal microscopy. After stimulation for 24 h with TPA and n-butryate as described above, the cells were dried on poly-L-lysinecoated coverslips (Marienfeld, Bad Mergentheim, Germany), fixed with acetone, and blocked for 1 h with 5% FCS in PBS. After incubation for 1 h with monoclonal antibody (MAb) vp4G2 (anti-HHV-8 VP23), kap5C4 (anti-HHV-8 K12), or 817 (anti-EBV VCA) (Chemicon, Temecula, Calif.) diluted in 5% FCS in PBS, the cells were incubated for 2 h with Cy3-conjugated goat anti-rat IgG or goat anti-mouse IgG (Sigma) diluted 1:200 in 5% FCS in PBS. MAbs vp4G2 (23a) and kap5C4 (21a) were generated as described elsewhere. The cells were washed and examined under a TNT confocal microscope DMIRB (Leica, Bensheim, Germany). Initially, six cell lines were established from PBMC of each donor and supernatant. PBMC from one donor were used twice, with a similar outcome. Thus, a total of 54 cell lines were established by using either BCBL-1 or BC-1 supernatant. HHV-8
RESULTS

Immortalization of PBMC and persistent viral infection by
ϩ EBV ϩ LCLs were tested after various passages for the presence of EBV and HHV-8 DNA by PCR (Fig. 1) . Both EBV and HHV-8 were present in all cell lines derived from PBMC of EBV ϩ donors infected with supernatant of the HHV-8 ϩ cell lines BC-1 and BCBL-1, as well as in cell lines derived from EBV Ϫ donors infected with supernatant of BC-1 cells. In the experiment in Fig. 1 , two LCLs, ABEH-1 and GMEH-1, were tested after 3, 6, 9, 12, 15, 18, and 21 passages Ϫ LCLs (ABE-1 and GME-1), BC-1, and BCBL-1 were stained with anti-CD3, anti-CD14, anti-CD16, and anti-CD19 MAbs. Isotype controls were included in each assay. Flow cytometry was performed by gating on 10,000 living cells.
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All four cell lines kept in continuous cell culture for more than 9 months were found to be positive for both EBV and HHV-8. Furthermore, none of the HHV-8 ϩ EBV ϩ LCLs have become negative for either HHV-8 or EBV thus far.
Phenotypic analysis of EBV ؉ HHV-8 ؉ LCLs. Next, we determined the phenotype of the immortalized cell lines. All HHV-8 ϩ EBV ϩ LCLs tested were positive for CD19 (B-lymphocyte antigen) but negative for CD3 (T-lymphocyte marker), CD14 (monocytes/macrophages), and CD16 (NK cells) (Fig. 2) , indicating that these cells are of B-lymphocyte origin. Moreover, HHV-8 ϩ EBV ϩ LCLs expressed surface IgM, as well as B-cell activation markers CD23, CD30, and CD80 similarly to EBVtransformed LCLs (Table 2) . Surface IgG, CD20, and CD56 were not found on these cells. The phenotype differed from BCBL-1 and BC-1 cell lines by some markers; e.g., BCBL-1 cells were negative for CD80, and BC-1 cells were negative for CD30. Intriguingly, the surface phenotype as well as growth characteristics varied between LCLs from different donors. Whereas most of the HHV-8 ϩ EBV ϩ LCLs grow in large conglomerates in suspension similar to EBV-transformed LCLs, cells of the HHV-8 ϩ EBV ϩ LCL COEH-1 show semiadherent growth and are spindle shaped (data not shown).
Latent infection of transformed B-cell lines by HHV-8. We next tested HHV-8
ϩ EBV ϩ LCLs for expression of the latent viral transcript T0.7, which codes for kaposin. T0.7 was detected in the noninduced HHV-8 ϩ EBV ϩ LCL GMEH-1 after 5, 10, and 15 passages by RT-PCR, and expression could be increased by induction with phorbol ester and n-butyrate (Fig.  3) . The signal resulting from the amplification of actin mRNA was similar for all samples tested, indicating that the RNA content was comparable. The RT-PCR result was confirmed by Northern blot analysis, which revealed the presence of T0.7 in unstimulated ABEH-1 and GMEH-1 cells after more than 25 passages. In accordance with the RT-PCR results, kaposin protein was detected in the noninduced HHV-8 ϩ EBV ϩ LCLs GMEH-1 and ABEH-1 by immunofluorescence with the MAb kap5C4 (Fig. 4) . Kaposin was also detected on BCBL-1 cells but not on B95-8 cells.
Induction of lytic viral proteins in HHV-8
؉ EBV ؉ LCLs. We next investigated whether latent HHV-8 can be reactivated in HHV-8 ϩ EBV ϩ LCLs. GMEH-1 and ABEH-1 LCLs after 5, 10, and 15 culture passages were stimulated with phorbol ester and n-butyrate and subsequently tested for lytic viral transcripts coding for VP23 by RT-PCR (Fig. 3) . In all immortalized HHV-8 ϩ EBV ϩ LCLs tested, lytic HHV-8 mRNA was detected after induction by phorbol ester and n-butyrate, similar to BC-1 and BCBL-1 cells. In accordance with the RT-PCR results, the viral capsid protein VP23 was detected by immunofluorescence with the MAb vp4G2 in cells of the HHV-8 ϩ EBV ϩ LCL ABEH-1 and in BCBL-1 cells. No reactivity was seen with B95-8 (Fig. 4) (Table 3) . As anticipated, supernatants of the EBV ϩ LCLs ABE-1 and GME-1 immortalized B cells. Intriguingly, incubation with supernatants of HHV-8 ϩ
EBV
ϩ LCLs also promoted the outgrowth of cell lines, whereas control supernatant of Raji cells or culture medium had no such effect. Six second-generation cell lines were established for each supernatant, and one second-generation cell line of each supernatant was tested by immunofluorescence analysis after two passages. Cell lines that were derived from PBMC incubated with supernatant of ABE-1 and GME-1 cells were found to be positive for EBV VCA and negative for HHV-8 kaposin. Cell lines that were derived from PBMC incubated with supernatant of cells of the HHV-8 ϩ EBV ϩ LCLs ABEH-1 and GMEH-1 were positive for both HHV-8 kaposin and EBV VCA, indicating that HHV-8 has been transferred to these cells.
DISCUSSION
In this study, we were able to show that (i) peripheral blood B lymphocytes can be persistently infected by HHV-8 in vitro, (ii) HHV-8 supports transforming activity of EBV on B cells, and (iii) infection leads to the outgrowth of permanent HHV- RT-PCR analysis of EBV ϩ HHV-8 ϩ LCL GMEH-1 was performed after 5, 10, and 15 passages either with or without induction by TPA and sodium butyrate. The RT reaction was performed by oligo(dT) priming followed by PCR with gene-specific primers for the latent T0.7 transcript (196 bp), the lytic viral mRNA VP23 (917 bp), and actin mRNA (245 bp) as a control. As negative and positive PCR controls, water and plasmid DNAs of full-length cDNA of VP23, actin, and K12 were used, respectively. IgG IgM CD20 CD23 CD30 CD56 CD80 tween 1 in 10 4 and 1 in 10 6 (43) . EBV present in isolated PBMC can lead to the spontaneous outgrowth of immortalized cells without the addition of EBV-containing supernatants; however, a minimal number of cells must be used (22, 23) . In the experiments shown here, the number of cells used was not sufficient for spontaneous outgrowth of EBV ϩ LCLs (Table 1 it appears to depend on an EBV-derived cofactor, at least under the conditions we used. An alternative explanation might be a two-step transformation process, divided into an initiating step and a maintaining step. In this case, the virus supplying the initiating step should be lost at least in some cell lines, since there is no selection for it. At the moment, however, we have no evidence for this explanation. Interestingly, HHV-8 has no homologs to EBNAs, LMPs, and EBERs; however, there are several other candidates for transforming genes like v-IL6 (29, 33) , cc-chemokines (21), G-protein-coupled receptor (3, 12) , v-cyclin (7, 8, 17) , K1 (14) , interferon regulatory factor (29, 31) , kaposin (32), v-FLIP (46), LANA (36) , and v-bcl2 (9) . Thus, the mechanism by which HHV-8 supports transformation might be different from that for EBV. It is known that peripheral blood B lymphocytes can be infected by HHV-8 in vivo in KS patients and healthy individuals (1, 10, 25) . At present, there is no evidence that these cells are doubly infected by HHV-8 and EBV in vivo (4). In contrast, almost all of the PEL tumors are positive for both EBV and HHV-8, implying that double infection could play a causal role in this entity. In KS, only a minority of tumors are positive for EBV. Thus, it is unlikely that both viruses in concert play a role in tumorigenesis of KS. The primary target cell of HHV-8 infection is not yet known. This study provides some evidence that B cells could be the primary reservoir and the place of latency in HHV-8-infected individuals with and without KS. It presents a model system of HHV-8 infection in vitro and might give some clues about the role of B-cell infection in the pathogenesis of HHV-8.
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